Physician profile
Jon E Tosino
NPI 1912960808
$22,194.33
in general payments reported to CMS, 2019-2025
68 companies · $2,264 in 2025
The $2,264 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,287 · 2020: $3,193 · 2021: $3,706 · 2022: $3,907 · 2023: $3,192 · 2024: $2,644 · 2025: $2,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,016 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,016.06 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,656.40 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $2,258.17 | 2019-2025 | |
| Novo Nordisk INC | $1,661.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,619.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $1,219.28 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $1,192.86 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $1,166.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $843.90 | 2019-2022 | |
| Allergan, INC. | $815.22 | 2019-2020 | |
| Amgen INC. | $745.46 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.37 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $544.85 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $466.83 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $421.56 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $392.23 | 2019-2025 | Xifaxan |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Tosino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.